<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399931</url>
  </required_header>
  <id_info>
    <org_study_id>2P-HD-10 STUDY</org_study_id>
    <nct_id>NCT01399931</nct_id>
  </id_info>
  <brief_title>Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions</brief_title>
  <acronym>2P-HD-10</acronym>
  <official_title>Dual Point Acquisition in the Interim Pet Scan Performed During ABVD Treatment, in Early-Stage Hodgkin's Lymphoma Patients With Bulky Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Santa Croce-Carle Cuneo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consorzio Mario Negri Sud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale Santa Croce-Carle Cuneo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess specificity and overall accuracy of interim dual-point acquisition PET in
      predicting treatment outcome.

      The study is aimed at assessing the specificity of interim dual-point PET performed after 2
      ABVD cycles to predict treatment outcome in early-stage Hodgkin's Lymphoma patients
      presenting bulky lesions at baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is an non-interventional survey of a cohort of patients in whom interim
      PET scan is performed only for prognostic aims.

      PET with 18F-FDG is a standard staging procedure for most lymphoma subtypes. Performed early
      during the therapy for Hodgkin's lymphoma (HL) its results have a high prognostic value and
      is the main predictor of treatment outcome. From 2006 onward, interim-PET after 2 ABVD
      courses has been increasingly performed in the daily clinical practice as a routine test for
      disease prognosis, and now it can be considered as a standard prognostic tool.

      The novelty of the study relies on a new method for interim-PET scan execution: a dynamic
      study, with 2 different time points of image acquisition. This could potentially enable us to
      discriminate between unspecific, inflammatory DG uptake, from a &quot;true&quot; uptake form persisting
      viable neoplastic cells. Therefore, the main aim of the study is reducing false positive
      results in the interim-PET scan interpretation. Since dynamic changes of FDG uptake in
      Hodgkin's lymphoma are still unknown we propose, in the present study, to assess the by the
      same acquisition technique the pattern of FDG uptake at baseline in untreated patients
      affected by this neoplasm.

      The Institutions equipped with a Magnetic Resonance scanners and a diffusion weighted imaging
      analysis technique (DW-MRI), could participate to the DW-MRI sub-study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>1 year</time_frame>
    <description>To assess feasibility of using interim dual-point acquisition PET in real world of clinical practice as well as describing the outcome of early stage HL patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of inflammation markers prognostic role</measure>
    <time_frame>3 years</time_frame>
    <description>To assess prognostic value of inflammation markers (ESR, CRP, Ferritin, Transferrin, Fibrinogen, Alpha 2-globulins) as biomarkers of treatment outcome in early stage HL patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Early-stage Hodgkin Lymphoma Patients</arm_group_label>
    <description>Early-stage Hodgkin Lymphoma (HL) patients presenting bulky nodal lesions treated with ABVD and consolidation radiotherapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Early-stage Hodgkin Lymphoma (HL) patients presenting bulky nodal lesions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hodgkin lymphoma diagnosis according all the WHO classification subtype but lymphocyte
             predominance.

          -  Age 18 - 60 years old

          -  stage IA- IIA (by FDG-PET scan)

          -  Presence of bulky tumour (either in Mediastinum or other site)

          -  Treatment with ABVD x 4 (early stage)

          -  Consolidation Radiotherapy on bulky lesion

          -  Signed the Informed consent form

        Exclusion Criteria:

          -  Diabetes mellitus uncompensated

          -  Lymphocyte predominance histology

          -  Pregnancy or lactation

          -  Implanted biomedical devices (for DW-MRI sub study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Gallamini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Sanitaria Ospedaliera Santa Croce e Carle Cuneo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ANDREA GALLAMINI, MD</last_name>
    <phone>+390171642414</phone>
    <email>gallamini.a@ospedale.cuneo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MARIA ROSARIA MENNITTO, PHARM D</last_name>
    <phone>+390171642415</phone>
    <email>mennitto.m@ospedale.cuneo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Santi Antonio E Biagio E Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALESSANDRO LEVIS, MD</last_name>
      <phone>+390131206156</phone>
      <email>alevis@ospedale.al.it</email>
    </contact>
    <investigator>
      <last_name>ALESSANDRO LEVIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria S. Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANGELO M CARELLA, MD</last_name>
      <phone>+39010513731</phone>
      <email>angelomichele.carella@hsmartino.it</email>
    </contact>
    <investigator>
      <last_name>ANGELO M CARELLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SILVIA BOLIS, MD</last_name>
      <phone>+390392339383</phone>
      <email>s.bolis@hsgerardo.org</email>
    </contact>
    <investigator>
      <last_name>SILVIA BOLIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DONATO MANNINA, MD</last_name>
      <phone>+390903992253</phone>
      <email>d.mannina@alice.it</email>
    </contact>
    <investigator>
      <last_name>DONATO MANNINA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PAOLO GAVAROTTI, MD</last_name>
      <phone>+393479632795</phone>
      <email>pgavarotti@molinette.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>PAOLO GAVAROTTI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera S. Croce E Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANDREA GALLAMINI, MD</last_name>
      <phone>+390171642414</phone>
      <email>gallamini.a@ospedale.cuneo.it</email>
    </contact>
    <contact_backup>
      <last_name>ALBERTO BIGGI, MD</last_name>
      <phone>00390171641558</phone>
      <email>biggi.a@ospedale.cuneo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Gallamini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007 Aug 20;25(24):3746-52. Epub 2007 Jul 23.</citation>
    <PMID>17646666</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>October 16, 2015</last_update_submitted>
  <last_update_submitted_qc>October 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Santa Croce-Carle Cuneo</investigator_affiliation>
    <investigator_full_name>DR. ANDREA GALLAMINI</investigator_full_name>
    <investigator_title>HEAD OF HAEMATOLOGY DEPT. A.S.O. S. CROCE AND CARLE</investigator_title>
  </responsible_party>
  <keyword>Early stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

